Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

NCT00368316 is registered in ClinicalTrials.gov with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as lead sponsor.

NCT NCT00368316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00368316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2003
Completion date
February 28, 2009
Enrollment
2,799 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

shigellosis